Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known.
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study
Guarneri, F;
2020-01-01
Abstract
Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jdv.17094.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
279.12 kB
Formato
Adobe PDF
|
279.12 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Dupilumab_therapy_of_atopic_dermatitis_o.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
123.06 kB
Formato
Adobe PDF
|
123.06 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
